Nabriva Therapeutics
Leberstrasse 20
Vienna
1112
Tel: 43-0-1-74093-0
Fax: 43-0-1-74093-1900
Website: http://www.nabriva.com/
Email: office@nabriva.com
180 articles about Nabriva Therapeutics
-
Nabriva Announces Closing of Rights Offering and Underwritten Offering
12/20/2016
-
Nabriva Achieves 60% Randomization Target In LEAP 1 Phase 3 Trial In Community Acquired Bacterial Pneumonia
12/20/2016
-
Nabriva Announces Results Of Rights Offering And Pricing Of Underwritten Offering
12/15/2016
-
Nabriva Announces Terms Of Rights Offering
11/30/2016
-
Nabriva Announces Change In Record Date For Planned Rights Offering
11/22/2016
-
Nabriva Reports Third Quarter 2016 Financial Results
11/16/2016
-
Nabriva Announces Planned Rights Offering And Sets Record Date
11/14/2016
-
Nabriva To Present At The 2016 Wedbush PacGrow Healthcare Conference
8/10/2016
-
Nabriva Reports Second Quarter 2016 Financial Results
8/9/2016
-
Nabriva Announces Nomination Of Candidates For Its Supervisory Board
7/25/2016
-
Nabriva To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
7/5/2016
-
Nabriva Reports First Quarter 2016 Financial Results
5/10/2016
-
Nabriva Provides Development Update And Reports Nine Month 2015 Financial Results
11/11/2015
-
Nabriva To Provide Development Update And Announce Nine Month 2015 Financial Results; Conference Call On Wednesday, November 11, 2015
11/4/2015
-
Nabriva Hires Will Sargent As Vice President Of Commercial Strategy And Investor Relations
10/14/2015
-
Nabriva Presents Data On Lefamulin At The 2015 ID Week In San Diego
10/13/2015
-
Nabriva Announces Closing Of Its Initial Public Offering
9/24/2015
-
Should You Invest in Nabriva IPO?
9/18/2015
-
Nabriva, REGENXBIO, and Penumbra Set to Go Public This Week
9/15/2015
-
Nabriva Appoints Elyse Seltzer MD As Chief Medical Officer
5/21/2015